跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 58 条关于
“KnectIQ”
全部
58
临床试验
18
药物
21
机构
1
资讯
18
11个月前
Technology Partnership Announcement: KnectIQ and SRC UK Licensing Agreement for Defense Intelligence Platforms
2年前
Enfortumab Vedotin Plus Pembrolizumab Shows Consistent Benefits in Urothelial Carcinoma Regardless of Nectin-4 Levels
去年
Mabwell's Nectin-4 ADC, 9MW2821, Advances with Two New Clinical Trial Approvals
去年
Novel CD28 x Nectin-4 Bispecific Antibody Shows Promise in Advanced Bladder Cancer Treatment
去年
Innate Pharma Doses First Patient in Phase 1 Trial of Nectin-4-Targeting ADC IPH4502 for Advanced Solid Tumors
去年
Mabwell's Nectin-4 ADC, 9MW2821, Receives Approval for Two New Clinical Trials in China
去年
Innate Pharma's IPH4502, a Nectin-4-Targeting ADC, Receives FDA IND Clearance for Phase 1 Solid Tumor Trial
去年
FDA Clears Phase 1b Trial for Novel Nectin-4 Targeted Radiopharmaceutical AKY-1189 Across Multiple Cancer Types
去年
Mabwell Initiates First US Clinical Trial of Nectin-4 ADC in Previously Treated Triple-Negative Breast Cancer
2个月前
Aptevo Files Patent for Nectin-4 x PD-L1 Dual-Targeting Backbone to Expand Solid Tumor Strategy
第 1 页,共 2 页
上一页
下一页